APVO 最新10-Q变化

将 APVO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。

对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-13

章节	结果	新增	删除	微调	未变
管理层讨论与分析	文字有新增/删除	+27	−28	~5	38
市场风险(第3项)	文字有新增/删除	0	0	~1	0
控制与程序	文字有新增/删除	0	0	~2	1
法律诉讼	无段落级文字变化	0	0	0	1
风险因素	部分风险因素更新	+28	−22	~20	274
其他信息	文字有新增/删除	0	0	~1	0

计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。

代表性摘录

每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。

管理层讨论与分析

相对上期新增的文字 · 来源:10-Q · 2026-08-14

Continued to advance the Phase 1b/2 RAINIER trial evaluating mipletamig in combination with venetoclax and azacitidine in frontline AML, with ongoing dose optimization activities supporting selection of a recommended Phase 2 dose.
Appointed Mary J. Janatpour, Ph.D., as Senior Vice President and Chief Scientific Officer to lead research and preclinical development and support advancement of the Company’s oncology pipeline.
Received a $1.5 million research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling activities for APVO451, the Company’s nectin-4-targeted trispecific immunotherapy candidate for solid tumors.
Entered into a 50/50 collaboration with Niowave to develop up to three radiopharmaceutical oncology programs; in connection with the collaboration, Niowave made an equity investment in the Company at closing.
Comparison of the three and six months ended June 30, 2026 and 2025

相对上期删除的文字 · 来源:10-Q · 2026-05-13

RAINIER trial on track for completion and Phase 2 dose selection by year end.
Mipletamig continues to generate strong data in frontline acute myeloid leukemia (AML) in combination with venetoclax + azacitidine. Across 31 evaluable patients (includes data through RAINIER Cohort 5, plus 4 patients from the previously completed dose expansion trial), the data has demonstrated co…
87% clinical benefit rate* demonstrates broad anti-leukemia activity and blast reduction across response categories
81% CR or CRi (remission), compared to 66.4% in the Phase 3 VIALE-A trial**
65% achieved CR (complete remission), compared to 37% in the Phase 3 VIALE-A trial**

风险因素

相对上期新增的文字 · 来源:10-Q · 2026-08-14

business opportunities. A failure to raise the additional funding or to effectively implement cost reductions would harm our business, results of operations and future prospects.
In addition, we are subject to certain contractual restrictions on our ability to raise capital. Under the Securities Purchase Agreement and the Warrant Inducement Letters, we agreed that from the date of such agreements until 3 months after the later of (i) the Stockholder Approval Date and (ii) th…
Our future capital requirements will depend on many factors, including:
Recent regulatory developments may affect our ability to access capital markets. In May 2026, the Securities and Exchange Commission proposed amendments to the registered offering framework that, if adopted, would expand eligibility to use Form S‑3 and eliminate the limitations currently applicable …
Various macroeconomic factors and political events have in the past and could adversely affect in the future our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resultin…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

Various macroeconomic factors and political events have in the past and could adversely affect in the future our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resultin…
products, which may lead to unpredictable economic consequences including inflation or trade wars. For example, inflation has negatively impacted the Company by increasing our labor costs through higher wages and operating costs. Supply chain constraints have led to higher inflation, which if sustai…
Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year, as a result of a variety of factors, including:
the level and timing of any milestone payments with respect to sales of IXINITY by Medexus;
the extent of any payments received from collaboration arrangements and development funding as well as the achievement of development and clinical milestones under collaboration and license agreements that we may enter into from time to time and that may vary significantly from quarter to quarter; a…

如何读 10-Q 的风险因素(第 1A 项)

10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:

指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。

这只是对文件结构的客观描述,不构成对风险高低的判断。

数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议

章节

结果

新增

删除

微调

未变

管理层讨论与分析

文字有新增/删除

+27

−28

市场风险(第3项)

文字有新增/删除

控制与程序

文字有新增/删除

法律诉讼

无段落级文字变化

风险因素

部分风险因素更新

+28

−22

~20

274

其他信息

文字有新增/删除

代表性摘录

每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。

管理层讨论与分析

相对上期新增的文字 · 来源:10-Q · 2026-08-14

Continued to advance the Phase 1b/2 RAINIER trial evaluating mipletamig in combination with venetoclax and azacitidine in frontline AML, with ongoing dose optimization activities supporting selection of a recommended Phase 2 dose.
Appointed Mary J. Janatpour, Ph.D., as Senior Vice President and Chief Scientific Officer to lead research and preclinical development and support advancement of the Company’s oncology pipeline.
Received a $1.5 million research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling activities for APVO451, the Company’s nectin-4-targeted trispecific immunotherapy candidate for solid tumors.
Entered into a 50/50 collaboration with Niowave to develop up to three radiopharmaceutical oncology programs; in connection with the collaboration, Niowave made an equity investment in the Company at closing.
Comparison of the three and six months ended June 30, 2026 and 2025

相对上期删除的文字 · 来源:10-Q · 2026-05-13

RAINIER trial on track for completion and Phase 2 dose selection by year end.
Mipletamig continues to generate strong data in frontline acute myeloid leukemia (AML) in combination with venetoclax + azacitidine. Across 31 evaluable patients (includes data through RAINIER Cohort 5, plus 4 patients from the previously completed dose expansion trial), the data has demonstrated co…
87% clinical benefit rate* demonstrates broad anti-leukemia activity and blast reduction across response categories
81% CR or CRi (remission), compared to 66.4% in the Phase 3 VIALE-A trial**
65% achieved CR (complete remission), compared to 37% in the Phase 3 VIALE-A trial**

风险因素

相对上期新增的文字 · 来源:10-Q · 2026-08-14

business opportunities. A failure to raise the additional funding or to effectively implement cost reductions would harm our business, results of operations and future prospects.
In addition, we are subject to certain contractual restrictions on our ability to raise capital. Under the Securities Purchase Agreement and the Warrant Inducement Letters, we agreed that from the date of such agreements until 3 months after the later of (i) the Stockholder Approval Date and (ii) th…
Our future capital requirements will depend on many factors, including:
Recent regulatory developments may affect our ability to access capital markets. In May 2026, the Securities and Exchange Commission proposed amendments to the registered offering framework that, if adopted, would expand eligibility to use Form S‑3 and eliminate the limitations currently applicable …
Various macroeconomic factors and political events have in the past and could adversely affect in the future our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resultin…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

Various macroeconomic factors and political events have in the past and could adversely affect in the future our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resultin…
products, which may lead to unpredictable economic consequences including inflation or trade wars. For example, inflation has negatively impacted the Company by increasing our labor costs through higher wages and operating costs. Supply chain constraints have led to higher inflation, which if sustai…
Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year, as a result of a variety of factors, including:
the level and timing of any milestone payments with respect to sales of IXINITY by Medexus;
the extent of any payments received from collaboration arrangements and development funding as well as the achievement of development and clinical milestones under collaboration and license agreements that we may enter into from time to time and that may vary significantly from quarter to quarter; a…

如何读 10-Q 的风险因素(第 1A 项)

10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:

指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。

部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。

全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。

这只是对文件结构的客观描述,不构成对风险高低的判断。

APVO 最新10-Q变化

代表性摘录

管理层讨论与分析

风险因素

如何读 10-Q 的风险因素(第 1A 项)

APVO 更多分析

APVO 最新10-Q变化

代表性摘录

管理层讨论与分析

风险因素

如何读 10-Q 的风险因素(第 1A 项)

APVO 更多分析